Intranasal administration of acetylcholinesterase inhibitors.
This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeutically viable formulation. In vivo testing confirmed achievement of therapeutically relevant drug levels that matched or exceeded those for oral dosing, with a dramatic reduction in undesired emetic responses. Intranasal drug delivery is an effective option for the treatment of Alzheimer's disease and other central nervous system disorders.
Costantino
Henry R
HR
Nastech Pharmaceutical Company Inc, 3830 Monte Villa Parkway, Bothell, WA 98021, USA. rick@costantinoconsulting.com
Leonard
Alexis Kays
AK
Brandt
Gordon
G
Johnson
Paul H
PH
Quay
Steven C
SC
D000281:Administration, Intranasal; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005702:Galantamine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans
D002800:Cholinesterase Inhibitors; D005702:Galantamine